Sanofi and GlaxoSmithKline have announced a delay to their COVID-19 vaccine candidate after Phase I/II results showed it produced a disappointingly low immune response.
Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback
Plus: Pfizer On Track In US, But Needs More Time In India
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.